Does Erasca (ERAS) Expanding ERAS-0015 to China Recast Its Global Oncology Ambitions? [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
entered a collaboration and supply agreement with Tango Therapeutics to test ERAS-0015 in combination with vopimetostat. This combination of broader geographic rights and a partnered combination-therapy study highlights how Erasca is working to increase the potential reach and versatility of its oncology pipeline. We'll now examine how the expanded ERAS-0015 rights in China and the Tango Therapeutics collaboration shape Erasca's investment narrative. This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality What Is Erasca's Investment Narrative? To own Erasca today, you have to believe in the long-term payoff from a high-risk, oncology-focused R&D story with no current revenue and ongoing annual losses of around US$124.55 million. The recent worldwide expansion of rights to ERAS-0015 into China, Hong Kong, and Macau, alongside the Tango Therapeutics collaboration, ties the near-term narrative even more tightly to this si
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines? [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatGlobeNewswire
- Tango Therapeutics (TNGX) had its "buy" rating reaffirmed by B. Riley Financial, Inc..MarketBeat
- Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX) [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics (TNGX) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $30.00 price target on the stock.MarketBeat
TNGX
Earnings
- 3/5/26 - Beat
TNGX
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- TNGX's page on the SEC website